FDA approves Hetlioz, first treatment for non-24 hour sleep-wake disorder in blind people

3 February 2014

The US Food and Drug Administration on Friday approved US drugmaker Vanda Pharmaceutical's (Nasdaq: VNDA) Hetlioz (tasimelteon), a melatonin receptor agonist, to treat non-24- hour sleep-wake disorder (“non-24”) in totally blind individuals.

Non-24 is a chronic circadian rhythm (body clock) disorder in the blind that causes problems with the timing of sleep. This is the first FDA approval of a treatment for the disorder, and follows a 10 to 0 vote from the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee (The Pharma Letter November 15, 2013).

Vanda in-licensed tasimelteon from Bristol-Myers Squibb in 2004 under a $41million deal, and last year B-MS waived its option to re-acquire rights. News of the approval pushed Vanda’s share up as much as 15%, but the stock settled back for a 1.3% rise to $13.23 by close of trading on January 31.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK